VERRICA PHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN PHASE 3 PROGRAM EVALUATING YCANTH® (VP-102) FOR THE TREATMENT OF COMMON WARTS

Reuters · 01/07 13:00

Please log in to view news